Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Gabriel Horta-Baas. (2022) Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?. Patient Related Outcome Measures 13, pages 79-95.
Read now
Read now
Kelly A. Reynolds, Deeti J Pithadia, Erica B Lee, George Han & Jashin J Wu. (2020) Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Expert Opinion on Drug Safety 19:4, pages 459-466.
Read now
Read now
Hiroaki Matsuno & Tsukasa Matsubara. (2019) A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Modern Rheumatology 29:6, pages 919-927.
Read now
Read now
Christopher J. Edwards, Jana Hercogová, Helene Albrand & Aurelian Amiot. (2019) Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy 19:10, pages 1001-1014.
Read now
Read now
Cătălin Codreanu, Klára Šírová, Katerina Jarošová & Anastas Batalov. (2018) Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. Current Medical Research and Opinion 34:10, pages 1763-1769.
Read now
Read now
Dae Hyun Yoo, Jung-Yoon Choe, Seung Cheol Shim & Chang-Hee Suh. (2018) Switching to biosimilars in the treatment of rheumatic diseases. Expert Review of Clinical Immunology 14:7, pages 557-571.
Read now
Read now
J. Braun & J. Kay. (2017) The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety 16:3, pages 289-302.
Read now
Read now
Articles from other publishers (41)
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Akimichi Morita, Mamitaro Ohtsuki, Yasuo Suzuki, Mamoru Watanabe, Hisashi Yamanaka & Toshifumi Hibi. (2023) Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Safety 46:10, pages 991-1005.
Crossref
Crossref
Bruno Fautrel, Yoram Bouhnik, Philippe Dieude, Pascal Richette, Maxime Dougados, Ulrich Freudensprung, Amira Brigui & Janet Addison. (2023) Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study. Rheumatology Advances in Practice 7:2.
Crossref
Crossref
Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko & Hirotaka Chikuda. (2022) Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13. BMC Rheumatology 6:1.
Crossref
Crossref
Akimichi Morita, Kiyohiro Nishikawa, Fumika Yamada, Keiichi Yamanaka, Hideki Nakajima & Mamitaro Ohtsuki. (2022)
Safety, efficacy, and drug survival of the infliximab biosimilar
CT‐P13
in post‐marketing surveillance of Japanese patients with psoriasis
. The Journal of Dermatology 49:10, pages 957-969.
Crossref
Crossref
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka & Hisashi Yamanaka. (2022) Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Modern Rheumatology 32:4, pages 718-727.
Crossref
Crossref
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers & Arif Soonasra. (2022) Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy 39:5, pages 2109-2127.
Crossref
Crossref
Jae Hee Cheon, Seongsu Nah, Hyoun Woo Kang, Yun Jeong Lim, Sang-Hoon Lee, Sang Joon Lee, Sung Hyun Kim, Na Hyun Jung, Jeong Eun Park, Yeo Jin Lee, Da Bee Jeon, Yeon Mi Lee, Jong Min Kim & Sung-Hwan Park. (2021) Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. Advances in Therapy 38:8, pages 4366-4387.
Crossref
Crossref
Anna M. BuchnerYecheskel SchneiderGary R. Lichtenstein. (2021) Biosimilars in Inflammatory Bowel Disease. American Journal of Gastroenterology 116:1, pages 45-56.
Crossref
Crossref
Ambre Lauret, Anna Moltó, Vered Abitbol, Loriane Gutermann, Ornella Conort, François Chast, Claire Goulvestre, Claire Le Jeunne, Stanislas Chaussade, Christian Roux, Frédéric Batteux, Maxime Dougados, Yannick Allanore & Jérôme Avouac. (2020) Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Seminars in Arthritis and Rheumatism 50:6, pages 1449-1456.
Crossref
Crossref
Liese Barbier, Hans C. Ebbers, Paul Declerck, Steven Simoens, Arnold G. Vulto & Isabelle Huys. (2020) The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology & Therapeutics 108:4, pages 734-755.
Crossref
Crossref
Kelly A. Reynolds, Deeti J. Pithadia, Erica B. Lee, Wilson Liao & Jashin J. Wu. (2020) Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. American Journal of Clinical Dermatology 21:4, pages 483-491.
Crossref
Crossref
Alexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Iain B McInnes, Johannes W Bijlsma, Gerd R Burmester, Maarten de Wit, Louise Falzon & Robert Landewé. (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 79:6, pages 760-770.
Crossref
Crossref
Tae-Hwan Kim, Shin-Seok Lee, Won Park, Yeong Wook Song, Chang-Hee Suh, SooKyoung Kim, Young Nam Lee & Dae Hyun Yoo. (2020) A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Clinical Drug Investigation 40:6, pages 541-553.
Crossref
Crossref
Jonathan Kay, Thomas Dörner, Paul Emery, Tore K Kvien & Ferdinand C Breedveld. (2020) Clinical trial and ‘real-world’ data support switching from a bio-originator to its biosimilar. Annals of the Rheumatic Diseases 79:4, pages e44-e44.
Crossref
Crossref
Roy Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls & Paul Declerck. (2020) Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy 7:1, pages 35-64.
Crossref
Crossref
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese & Ji Hoon Jeong. (2020) The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80:2, pages 99-113.
Crossref
Crossref
Hyoun-Ah Kim, Eunyoung Lee, Sun-Kyung Lee, Yong-Beom Park, Young Nam Lee, Hee Jung Kang & Kichul Shin. (2019) Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. BioDrugs 34:1, pages 89-98.
Crossref
Crossref
Shin-ya Kawashiri, Toshimasa Shimizu, Shuntaro Sato, Shimpei Morimoto, Yurika Kawazoe, Remi Sumiyoshi, Naoki Hosogaya, Chizu Fukushima, Hiroshi Yamamoto & Atsushi Kawakami. (2020) Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I). Medicine 99:30, pages e21151.
Crossref
Crossref
Carmen Tze Kwan Ho, Chi Chiu Mok, Tommy Tsang Cheung, Kitty Yan Kwok & Ronald Man Lung Yip. (2019) Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. Clinical Rheumatology 38:12, pages 3331-3350.
Crossref
Crossref
Edward Mezones-Holguin, Rocio Violeta Gamboa-Cardenas, Gadwyn Sanchez-Felix, José Chávez-Corrales, Luis Miguel Helguero-Santin, Luis Max Laban Seminario, Paula Alejandra Burela-Prado, Maribel Marilu Castro-Reyes & Fabian Fiestas. (2019) Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country. Frontiers in Pharmacology 10.
Crossref
Crossref
Hans C. Ebbers & Huub Schellekens. (2019) Are we ready to close the discussion on the interchangeability of biosimilars?. Drug Discovery Today 24:10, pages 1963-1967.
Crossref
Crossref
Ouafa Mkinsi, Salima Lefkir-Tafiani, Héla S, Srairi, Samir Kochbati, Yasser M. El Dershaby, Mohamed M. El Azhari, Sabrina A-I. Midjek & Aicha Ladjouze-Rezig. (2019) Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. The Open Rheumatology Journal 13:1, pages 72-84.
Crossref
Crossref
Jonathan Kay. (2019) Are There Benefits and Risks to Biosimilars from a Patient Perspective?. Rheumatic Disease Clinics of North America 45:3, pages 465-476.
Crossref
Crossref
Kaltsonoudis Evripidis, Pelechas Eleftherios, Voulgari V. Paraskevi & Drosos A. Alexandros. (2019) Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study. Journal of Clinical Medicine 8:7, pages 956.
Crossref
Crossref
Fabrizio Cantini & Maurizio Benucci. (2019) Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?. Annals of the Rheumatic Diseases 78:4, pages e23-e23.
Crossref
Crossref
Brian G. Feagan, Gordon Lam, Christopher Ma & Gary R. Lichtenstein. (2019) Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Alimentary Pharmacology & Therapeutics 49:1, pages 31-40.
Crossref
Crossref
Prasan Deep Rath, Der-Yuan Chen, Jieruo Gu, Vivian W. Y. Lee, Nizar Abdulateef Al Ani, Khalid Shirazy & Lyndon Llamado. (2019) Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region. International Journal of Rheumatic Diseases 22:1, pages 9-24.
Crossref
Crossref
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto & Jorge A. Dias. (2019) Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. Journal of Pediatric Gastroenterology & Nutrition 68:1, pages 144-153.
Crossref
Crossref
Georgios Bakalos & Elias Zintzaras. (2019) Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Clinical Therapeutics 41:1, pages 155-173.e13.
Crossref
Crossref
Evrydiki Kravvariti, George D. Kitas, Dimos D. Mitsikostas & Petros P. Sfikakis. (2018) Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nature Reviews Rheumatology 14:12, pages 727-740.
Crossref
Crossref
Masahiro Tsuda, Yuki Otani, Atsushi Yonezawa, Sho Masui, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari & Kazuo Matsubara. (2018) Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS. Biological and Pharmaceutical Bulletin 41:11, pages 1716-1721.
Crossref
Crossref
Johlee S. OdinetChelsea E. DayJennifer L. CruzGregory A. Heindel. (2018) The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. Journal of Managed Care & Specialty Pharmacy 24:10, pages 952-959.
Crossref
Crossref
Syed Numan & Freddy Faccin. (2018) Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. Advances in Therapy 35:9, pages 1295-1332.
Crossref
Crossref
Antonio Pires, Kavitha Goyal & Andrew Greenspan. (2018) Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”. Drugs 78:8, pages 851-852.
Crossref
Crossref
Jose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel & Robert Strohal. (2018) Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. Dermatology and Therapy 8:2, pages 173-194.
Crossref
Crossref
N. Gonzalez, P. Patel & G. Han. (2018) A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar. British Journal of Dermatology 178:4, pages 965-968.
Crossref
Crossref
S. Louis BridgesJr.Jr., Douglas W. White, Angus B. Worthing, Ellen M. Gravallese, James R. O'Dell, Kamala Nola, Jonathan Kay & Stanley B. Cohen. (2018) The Science Behind Biosimilars. Arthritis & Rheumatology 70:3, pages 334-344.
Crossref
Crossref
Ross A. McKinnon, Matthew Cook, Winston Liauw, Mona Marabani, Ian C. Marschner, Nicolle H. Packer & Johannes B. Prins. (2018) Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. BioDrugs 32:1, pages 27-52.
Crossref
Crossref
Dae Hyun Yoo. (2017) Comparative effectiveness of the biosimilar CT-P13. Journal of Comparative Effectiveness Research 6:8, pages 693-712.
Crossref
Crossref
Hendrik Schulze-Koops & Alla Skapenko. (2017) Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology 56:suppl_4, pages iv30-iv48.
Crossref
Crossref
Robert Moots, Valderilio Azevedo, Javier L. Coindreau, Thomas Dörner, Ehab Mahgoub, Eduardo Mysler, Morton Scheinberg & Lisa Marshall. (2017) Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Current Rheumatology Reports 19:6.
Crossref
Crossref